Abstract

BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODS: All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTS: Nineteen patients were identified. The median age was 38 years (range 18–62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSION: Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
Also, the platelet-derived growth factor receptors (PDGFRs) \cite{7,8} and the signal transduction pathways of phosphatidylinositol 3'-kinase/mammalian target of rapamycin (PI3K/mTOR) \cite{9} play a role in the prognosis of osteosarcoma patients. For chondrosarcoma, different isoforms for VEGFR are involved in the tumor development \cite{10}. Sorafenib is an orally active multikinase inhibitor that targets MAPK, VEGFRs, and PDGFRs, which has been demonstrated to be effective in patient with high-grade osteosarcoma after failure of standard treatments \cite{11-13}. All these studies are small and investigate only a few patients.

A few case reports have demonstrated an effect of pazopanib in bone sarcoma. One study has investigated the effect on refractory Ewing sarcoma \cite{14} and two other on metastatic osteosarcoma \cite{15,16} both with promising results.

Treatment of bone sarcoma with pazopanib is an example for off-label use of an experimental drug which can be approved by the Danish Medical Council on doctors' request. In this article, we report our experience on treating metastatic bone sarcoma with pazopanib as an experimental drug.

**Material and Method**

**Study Cohort**

All patients diagnosed with bone sarcoma and treated with pazopanib for metastatic disease at Aarhus Sarcoma Centre were included in the study. The first patient was treated on October 1st, 2011, and the study period ended October 1st, 2017 to ensure a proper follow-up time for all patients included. Patients with extraskeletal bone sarcoma were excluded from the analysis. This resulted in a cohort of 21 patients. However, two patients were excluded because of death before pazopanib treatment was initiated. See Figure 1 for potential candidate for pazopanib treatment and reason for exclusion.

**Data Sources**

Clinical data were obtained from the newly validated population-based Aarhus Sarcoma Registry (ASR) and the National Quality Sarcoma Database \cite{17}, which contains comprehensive clinical information on each sarcoma patient from 1979 to 2019.

**Treatment**

Patients were diagnosed and treated, according to national guidelines, by an experienced multidisciplinary sarcoma team. The decision of using off-label pazopanib was made by the consultant in charge of bone sarcoma treatment. The study drug was taken orally once daily. The patients were seen on day 10, at week 4, and every 12 weeks thereafter. Treatment continued until disease progression according to RECIST criteria, unacceptable toxic effects, or death. Twelve-lead electrocardiograms and a multigated acquisition (MUGA) scan were assessed before the start of treatment. Only grade 3 or 4 toxicities are reported in this study and no differentiation based on grade 3 and 4 toxicities are made.

**Data Analysis and Statistics**

The primary endpoint was progression free survival (PFS) defined as time from start of pazopanib treatment to either disease progression or death from any cause. Patients alive at the time of analysis were censored. Secondary endpoint was OS. The study period ended October 1st, 2017. However, the patients were followed until February 1st, 2019. Patients alive at this date were censored. Descriptive data are presented and PFS is illustrated using a Kaplan–Meier plot. All statistical analyses were performed by using Stata version 15.

**Ethics**

The Ethics Committee of Denmark (1-10-72-233-12) and the Danish Agency of Data Protection (1-16-02-677-15) have approved the study.

**Results**

From October 2011 to October 2017, 19 patients from Aarhus Sarcoma Centre were treated with pazopanib for metastatic bone sarcoma. The median age at the beginning of pazopanib treatment was 39 years (range 18–62 year) and median duration between the diagnosis of bone sarcoma and the beginning of pazopanib was 2.7 years (range 0.8–38 year). A median of two prior treatment modalities of chemotherapy (range 0–6) was administrated before start of pazopanib and all patients had radiological progression disease at the start of pazopanib. For patient, tumor and treatment characteristic at the time of diagnosis, see Table 1, at start of pazopanib treatment, see Table 2.

**Response to Treatment**

Fifteen patients started with full dose of pazopanib (800 mg daily), one with reduced dose of 600 mg daily and three patients with 400 mg daily based on physicians’ evaluation of patients’ performance status and comorbidity. Of the 19 patients, 13 patients had clinical benefit in the form of partial response (6 patients) or stable disease (7 patients) as best response, 4 patients had progression of the disease as best response, and 2 patients were not evaluated as they died within 8
weeks after treatment with pazopanib was initiated. All patients stop treatment because of progression at the time of evaluation.

Four patients with chondrosarcoma were included in this study, two patients had low-grade tumors, one patient had intermediate-grade tumor, and one patient had high-grade tumor. The two patients with low-grade tumors had stable disease as best response, whereas the patients with high- or intermediate-grade tumors both progressed and did not have any effect of Pazopanib. The rest of the patients treated with pazopanib had a high-grade malignancy.

Patients with partial response had all high-grade tumors, three patients with osteosarcoma, one patient with radiation-induced osteosarcoma, one patient with Ewing sarcoma, and one patient with spindle cell sarcoma. For these patients, the median time from the start of pazopanib treatment until progression was 8.4 months (range min—max: 2.7—19.3).

**Toxicity to Treatment**

Five patients did not experience any grade 3/4 toxicity during pazopanib treatment. Ten patients experienced one or two grade 3/4 toxicities and four patients had more than two grade 3/4 toxicities during pazopanib treatment. Pazopanib-related grade 3 or 4 toxicities are summarized in Table 3. No toxic deaths were reported. Five patients were reduced in pazopanib dose because of toxicity and two patients terminated treatment because of toxicity.

**Follow-Up and Progression Free Survival**

The median follow-up time after start of pazopanib treatment was 10 months (range 1.5—41 months). The median OS rate from the start of pazopanib treatment was 11 months (85% CI: 5.4—19.3). The median PFS from start of pazopanib treatment was 5.5 months (95% CI: 2.7—7.7). Figure 2 shows the PFS from start of pazopanib treatment to progression. Three patients have a PFS >15 months. None of these patients had the same histological subtype.

Eight patients were treated after progression of pazopanib and for eleven patients pazopanib was the last treatment received. Four

---

Table 1. Patient Characteristic at Time of Diagnosis

| Primary Tumor n (%)                     |
|-----------------------------------------|
| Age                                     |
| Mean (range)                            | 35 (10—54) |
| Gender                                  |
| Male                                    | 14(74)     |
| Female                                  | 5 (26)     |
| Stage                                    |
| Localized advanced                      | 13(68)     |
| Metastatic                              | 6(32)      |
| Comorbidity                             |
| No                                      | 16(84)     |
| Yes                                     | 3(16)      |
| Primary Location                        |
| Extremities                             | 10(53)     |
| Thorax/pelvis                           | 9(47)      |
| Histology                               |
| Osteosarcoma                            | 8(42)      |
| Chondrosarcoma                          | 4(21)      |
| Ewing sarcoma                           | 3(16)      |
| Spindle cell/other                      | 4(21)      |
| Treatment                               |
| Surgery                                 | 4(21)      |
| Surgery + Ch/RT                         | 10(52)     |
| Surgery + RT + Ch                       | 3(16)      |
| Chr + RT                                | 2(11)      |
| Primary Cured                           |
| Yes                                     | 16(84)     |
| No                                      | 3(16)      |

RT: radiation therapy, Chr: Chemo therapy.

---

Table 2. Patient Characteristic at Start of Pazopanib Treatment

| Start of Pazopanib n (%)                        |
|-------------------------|
| Age                     |
| Median (range)          | 39(18–62) |
| Site of Metastasis      |
| Lung                    | 1(5)      |
| Extra pulmonary         | 2(11)     |
| Lung and extra pulmonary| 11(58)    |
| Local                   | 5(26)     |
| Time from Diagnosis     |
| Median in year (range)  | 2.67(0.8—38) |
| Treatment Before Pazopanib |
| Median number of lines  | 2(0—6)    |
| Median number of cycles | 18.5(4—20) |
| Pazopanib Start Dose    |
| 800 mg                  | 15(79)    |
| 600 mg                  | 1(5)      |
| 400 mg                  | 3(16)     |
| Best Response to Pazopanib |
| Partial response        | 6(32)     |
| Stable disease          | 7(37)     |
| Progression             | 4(21)     |
| Not evaluable           | 2(11)     |

1 Treatment given for metastatic disease.
2 For patient who were treated with chemotherapy before pazopanib.

---

Table 3. Pazopanib Related Toxicity (Grade 3/4)

|                  | Number (%) |
|------------------|------------|
| Hematological    | 2(11)      |
| Neutopenia       | 1(5)       |
| Elevated lever parameters | 2(11)   |
| Elevated creatinine | 1(5)    |
| Elevated blood pressure | 3(16) |
| Fatigue          | 5(26)      |
| Mucositis        | 2(11)      |
| Others           | 6(32)      |
| Diarrhea         | 3(16)      |

---

Figure 2. Progression free survival for patient with metastatic bone sarcoma treated with pazopanib. The number of patients is 19. All patients have at the time of follow-up progressed.
patient received chemotherapy, two patient other tyrosine kinases inhibitors, and two patients received more than one treatment modalities. Figure 3 shows a swimmer plot from the start of pazopanib treatment until progression or death.

Discussion
Despite different salvage strategies, refractory or metastatic bone sarcoma is usually fatal. Given the limited success of chemotherapy, efforts focusing on identifying targetable molecules are needed. Our results showed that pazopanib is well tolerated and seem to have a benefit in terms of PFS. When metastatic or recurrence has occurred, the prognosis is much poorer as chemotherapy resistance develops, along with the lack of a recommended second-line treatment for refractory metastatic osteosarcoma, new modalities must be explored.

Pazopanib is a second-generation selective multitargeted receptor TKI and objective responses to treatment with a vascular endothelial growth factor receptor inhibitor have been observed in patients with Ewing sarcoma, synovial sarcoma, and osteosarcoma [16,18]. A resent paper on pazopanib treatment of relapsed osteosarcoma patients find a PFS of 6 months which is in accordance with our findings [16]. A study published by Seto et al. including 18 bone sarcoma patients of different histology showed a disease control rate (DCR) for bone sarcoma of 39% [19]. Our results show a DCR of 68% which much higher. Furthermore, the response rates, progression free survival, and overall survival shown in our study are comparable with the efficacy shown using sorafenib either alone or in combination with Everolimus [11–13].

In terms of toxicity, pazopanib appeared to be an acceptable treatment. The toxicity profile in our cohort is in line with the PALETTE study [4].

“In 2018 Duffaud et al. published a randomized double-blinded placebo-controlled phase 2 study investigating the efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma. They showed that regorafenib was well tolerated and that the PFS was 16.4 weeks with a DCR of 64% and 8% of the patients were partial responders. These results are comparable with our result on pazopanib [20].” “However, a limitation of this study is the retrospective nature or our study, the low number of patients treated with pazopanib along with the fact that these patients represent many different histological subtypes with different prognosis. Osteosarcomas represent highly aggressive tumors and Chordomas represent slow-growing tumors. These differences should be taken into account with interpreting the results of this paper”.

Multimodal treatment including chemotherapy and/or radiation therapy might be necessary and the role for pazopanib in this setting needs further investigations in bone sarcomas. The addition of chemotherapy to Pazopanib treatment has been tested in malignant melanoma with manageable toxicity. The foremost grade 3 toxicity was increase in alanine aminotransferase [21]. The combination of radiation therapy with pazopanib had been tested in the adjuvant treatment of breast cancer patient that developed less dermatological toxicity than matched control groups treated with radiation therapy alone [22]. Furthermore, ongoing trials are currently assigning the addition of pazopanib to radiotherapy in the neoadjuvant treatment of STS [23].

Our article suggests that antiangiogenic molecules alone could be useful in the treatment of bone sarcomas and further research investigating the role of pazopanib in bone sarcoma could be investigated in a phase II trial. Future studies on Pazopanib alone or in combination with chemotherapy could with advantage be compared with regorafenib either alone or also in combination with chemotherapy in randomized trial.

In conclusion, our data suggest that pazopanib have some activity against bone sarcoma. Pazopanib is approved for STS treatment and therefore available for treating bone sarcoma. Yet, despite the evidence indicating that pazopanib can stabilize the disease, the PFS and OS are still poor for patients with metastatic bone sarcoma.

References

[1] Kager L, Zoubek A, Potschger U, Kastner U, Fliege S, Kempf-Bielack B, Branscheid D, Kitz R, Salzer-Kuntschik M and Winkelmann W, et al (2003). Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10), 2011–2018.
[2] Group EESNW (2016). Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3), iii13–23.
[3] Schutz FA, Choueiri TK and Sternberg CN (2011). Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 77(3), 163–171.
[4] van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP and Beppu Y, et al (2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 379(9829), 1879–1886.
[5] Coens C, van der Graaf WT, Blay JY, Chawla SP, Judson I, Sanfilippo R, Manson SC, Hodge RA, Marreaud S and Prins JB, et al (2015). Health-related quality-of-life results from PALETTE: a randomised, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organisation for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer 121(17), 2933–2941.
[6] Abeebe A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, Kim M, Wang D, Moody K and Gorlick R (2009). Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 115(22), 5243–5250.
[7] McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ and Bar-Eli M (2002). Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor ST571. Clin Cancer Res 8(11), 3584–3591.
[8] Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA and Healey JH, et al (2008). Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 112(10), 2119–2129.

[9] Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverria C, Mercuri M and Picci P, et al (2010). NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16(2), 530–540.

[10] Yukata K, Matsui Y, Goto T, Kubo T and Yasui N (2005). Differential expression of VEGF isoforms and VEGF receptors in cartilaginous tumors. Anticancer Res 25(2A), 955–957.

[11] Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Tamburini A, Pignochino Y, Sangiolo D and Marchesi E, et al (2015). Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 16(1), 98–107.

[12] Raciborska A and Biłska K (2018). Sorafenib in patients with progressed and refractory bone tumors. Med Oncol (Northwood, London, England) 35(10), 126.

[13] Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D and Marchesi E, et al (2015). Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 16(1), 98–107.

[14] Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N and Marotti M, et al (2010). A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28(35), 5174–5181.

[15] Safwat A, Boysen A, Lucke A and Rossen P (2014). Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol 53(10), 1451–1454.

[16] Rosten E, Pauli A, Palmerini E, Cesari M, Abate ME, Setola E, Spinnato P, Donati D, Hompland I and Boye K, et al (2019). Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncol 58(1), 124–128.

[17] Maretty-Nielsen K, Aggerholm-Pedersen N, Keller J, Safwat A, Baerentzen S and Pedersen AB (2013). Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark. Clin Epidemiol 5, 45–56.

[18] Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N and Marotti M, et al (2010). A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28(35), 5174–5181.

[19] Seto T, Song MN, Trieu M, Yu J, Sidhu M, Liu CM, Sam D and Pan M (2019). Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California. Med Sci (Basel) 7(3).

[20] Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Tamburini A, Pignochino Y, Sangiolo D and Marchesi E, et al (2015). Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 16(1), 98–107.

[21] Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheeler M, Plummer E, Mauch C and Scudder C, et al (2019). Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Ann Oncol 30(2), 317–324.

[22] Goyal S, Shah S, Khan AJ, Danish H and Haffty BG (2012). Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib. ISRN Oncol 2012, 896202.

[23] Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B and Teicher BA, et al (2014). Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst 106(11), https://doi.org/10.1093/jnci/dju329. Print 2014 Nov.